Favipiravir has been shown to be ineffective against COVID-19 in clinical trials 
Avigan (failed to show) its effectiveness in treating patients with mild to moderate severity of COVID-19. This was reported in a statement by the clinical trial company Appili.
The third phase of the PRESECO (PREventing SEvere COVID-19) double-blind, randomized clinical trial enrolled 1,231 coronavirus patients from Brazil, Mexico and the United States. All of them soon – no more than 72 hours later – after a positive PCR test were offered to take the pills at home under the supervision of researchers. clinical recovery, Appili said in a statement. “While we are disappointed with the results of the PRESECO study, we remain firmly convinced that safe and effective oral antiviral drugs are urgently needed in patients struggling with COVID-19. We would like to thank all the patients who participated [in the study], and we hope that the information obtained from our study will help research into more effective treatment options for COVID-19, ”said Arman Balboni, Director of Appili.
On November 12, favipiravir (produced in Russia under the name “Areplivir”) received, according to the statement of its developer, GK Promomed, a registration certificate from the Ministry of Health.